Genotypes of M tuberculosis from the TB patients with recurrence or treatment failure

Abstract

Abstract: ObjectiveTo analyze the genotypes of M. tuberculosis from the TB patients with recurrence or treatment failure. MethodsTuberculosis (TB) inpatients who had strains isolated from two successive episodes separated for at least 6 months were selected from Beijing Tuberculosis & Thoracic Tumor Institute during January 2000 to December 2007. The sequential isolates from the patients were analyzed by M. tuberculosis genotyping Methods to find out if the profiles matched. Results24 patients recruited into the study. The genotype patterns of recurrent M.tuberculosis isolates from the 5 patients previously completed treatment exhibited identical genotypes, indicating endogenous reactivation. Of 19 isolates from 8 patients defaulted from treatment and 11 patients with treatment failure, genotype patterns of 2 isolates (10.5%) did not match with those of the corresponding initial isolates, indicating reinfection. Isolates from the remaining 17 （89.5%） patients had identical genotype profiles results, suggesting treatment failure.ConclusionsThe endogenous reactivation and treatment failure may be a main cause for the recurrence of TB cases.

Key words: Tuberculosis,pulmonary/therapy, Treatment failure, Mycobacterium tuberculosis, Genotype

Wang Shengfen, Zhao Yanlin, ZhouYang, Zhao Bing, Zhao Liping, XiaHui, Dong Lingling.. Genotypes of M tuberculosis from the TB patients with recurrence or treatment failure[J]. Chinese Journal of Antituberculosis, 2009, 31(8): 464-468.

References

[1] Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results[J]. Ann Intern Med, 1990,112(6): 397-406.
[2] Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months[J]. Am Rev Respir Dis, 1991,143(4): 700-706.
[3] Barnett GD, Grzybowski S, Styblo K. The current risk of contracting evolutive tuberculosis, in Saskatchewan, according to the state of previous tuberculin tests and x-ray image[J]. Bull Int Union Tuberc, 1971, 45: 55-79.
[4] Canetti G, Sutherland I,Svandova E. Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis[J]. Bull Int Union Tuberc, 1972, 47:116-134.
[5] Kim BJ, Lee SH, Lyu MA, et al. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, Kim EC, Cha CY, Kook YH. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB) [J]. J Clin Microbiol, 1999, 37(6): 1714-1720.
[6] Frothingham R, and WA Meeker-O’Connell. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats[J]. Microbiology, 1998, 144:1189-1196.
[7] Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology[J]. J Clin Microbiol, 1997, 35(4): 907-914.
[8] van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM. Strain Identification of Mycobacterium tuberculosis by DNA Fingerprinting: Recommendations for a Standardized Methodology[J]. J Clin Microbiol, 1993, 31(2): 406-409.
[9] van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment[J]. N Engl J Med, 1999,341(16): 1174-1179.
[10] Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ; Tuberculosis Trials Consortium.Recurrent tuberculosis in the United States and Canada relapse or reinfection？[J]. Am J Respir Crit Care Med, 2004, 170(12): 1360-1366.
[11] Shamputa IC, Van Deun A, Salim MA, Hossain MA, Fissette K, de Rijk P, Rigouts L, Portaels F. Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection[J]. Trop Med Int Health, 2007,12(6): 700-708.
[12] 沈国妙, 薛桢, 沈鑫, 桂晓红, 王奕峰, 孙斌, 沈梅, 梅建, 高谦.利用结核分枝杆菌基因型分型技术研究外源性再感染在结核病复发中的作用[J].中华结核和呼吸杂志，2006，29（2）：79-82.
[13] Sonnenberg P, Murray J, Shearer S, Glynn JR, Kambashi B, Godfrey-Faussett P. Tuberculosis treatment failure and drug resistance-same strain or reinfection?[J]. Trans R Soc Trop Med Hyg, 2000, 94(6): 603-607.
[14] Bandera A, Gori A, Catozzi L, Degli Esposti A, Marchetti G, Molteni C, Ferrario G, Codecasa L, Penati V, Matteelli A, Franzetti F. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis[J]. J Clin Microbiol, 2001, 39(6): 2213-2218.

[1]	Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768.
[2]	YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806.
[3]	ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813.
[4]	ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820.
[5]	DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831.
[6]	QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879.
[7]	SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717.
[8]	ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740.
[9]	XU Yan, LU Xi-wei, CAI Chun-kui, SUN Shi-xue, GU Xiao-feng, YU Yang, LI Gang, WANG Ying. Retrospective study of CT imaging evolution of treatment failure patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 549-557.
[10]	HONG Chuang-yue, YANG Ting-ting, LI Jin-li, LI Shuang-jun, WU Li-kai, YANG Zheng, TAN Wei-guo. Analysis of characteristic of resistant gene mutations among multidrug-resistant Mycobacterium tuberculosis in Shenzhen [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 583-589.
[11]	LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488.
[12]	ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365.
[13]	ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379.
[14]	YANG Han,YANG Jing-fen,WU Hao,CUI Xiao-li,DANG Li-yun. Value of MicroDST test in detecting sensitivity of first-line anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 380-384.
[15]	CHEN Yan-mei,HUANG Xin-chun,SUN Qi,ZHANG Chen-chen,WEN Wen-pei,CHEN Liang. Analysis of drug resistance in patients with smear-negative and culture-positive pulmonary tuberculosis in Guangdong province in 2016 [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 272-275.